Former FDA officials and pharma groups weigh in as Supreme Court considers mifepristone regulation

The Supreme Court is expected to act on a case involving the abortion pill mifepristone after a pause on a federal appeals court order that halted mail‑order distribution.

The decision could reshape how the FDA’s drug‑approval authority interacts with state abortion laws, raising the question of whether states can impose stricter rules than the agency.

Former FDA leaders and representatives from pharmaceutical companies have publicly voiced concerns, emphasizing that the agency should remain the primary regulator of drug safety and access.

Policy experts note that the outcome may set a precedent for future drug‑regulation disputes, potentially affecting other medications subject to state‑level restrictions.